Mr. Stephen Van Deventer reports

PREVECEUTICAL ANNOUNCES MAILING AND FILING OF ANNUAL GENERAL AND SPECIAL MEETING MATERIALS IN CONNECTION WITH A PROPOSED ARRANGEMENT WITH BIOGENE THERAPEUTICS

Preveceutical Medical Inc., further to its news release of Sept. 4, 2025, has filed with the applicable Canadian securities regulatory authorities the management information circular dated Sept. 9, 2025, and related meeting materials of the company for use at the annual general and special meeting of shareholders of Preveceutical, to be held in connection with the proposed plan of arrangement to be effected under Part 9, Division 5, of the Business Corporations Act (British Columbia), with BioGene Therapeutics Inc., pursuant to which Preveceutical intends to spin out 12 million common shares of BioGene to the Preveceutical shareholders on a pro rata basis. The company obtained an interim order from the British Columbia Supreme Court on Sept. 9, 2025, authorizing the company to call the meeting. The meeting has been scheduled for Oct. 10, 2025, and the meeting materials have been mailed to the Preveceutical shareholders entitled to vote at the meeting. The meeting materials are available on the company's SEDAR+ profile and on the company's website.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.